Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells
Jordi Codony‐Servat(Hospital Universitario Dexeus), Joan Albanell(Universitat Pompeu Fabra)
Cited by 107
Related Papers
Phase I-II Study of Paclitaxel, Cisplatin, and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium
|Journal of Clinical Oncology|2000|191
Predicting response and survival in chemotherapy-treated triple-negative breast cancer
|British Journal of Cancer|2014|113
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer
|British Journal of Cancer|2017|76
Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines
|Translational Lung Cancer Research|2019|17